Dark Blue Therapeutics
Exposing cancer’s hidden vulnerabilities
Some of the most aggressive cancers, such as acute myeloid leukaemia (AML), depend on molecular ‘Achilles’ heels’ – critical weaknesses that can be targeted, if they’re found.
Dark Blue Therapeutics is developing precision oncology therapies that exploit these cancer-specific vulnerabilities. By combining cutting-edge academic research with deep industry expertise, the company is advancing a new generation of treatments designed to outsmart the toughest cancers.
Sector
Life Sciences
Stage
- Exited